ARTICLE | Emerging Company Profile
Carolus: Targeting cytokines
Carolus developing anti-inflammatory peptides with better safety profile
August 2, 2010 7:00 AM UTC
While cytokines are known to be effective targets to treat autoimmune and inflammatory diseases, inhibiting these molecules can restrict the defensive functions of the immune system and increase a patient's susceptibility to infection. Carolus Therapeutics Inc. believes its peptides can reduce inflammation while avoiding immunosuppression by specifically disrupting the interactions of pro-inflammatory cytokines.
President and CEO Court Turner told BioCentury that the problem with most potent anti-inflammatory agents that target cytokines is that "they are so competitive that they block all cognate ligands, and you start running into side effects."...